- Home
- MED vs MOLN Comparison
MED vs MOLN Comparison
Compare MED & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MED
- MOLN
- Stock Information
- Founded
- MED 1980
- MOLN 2004
- Country
- MED United States
- MOLN Switzerland
- Employees
- MED N/A
- MOLN N/A
- Industry
- MED Packaged Foods
- MOLN
- Sector
- MED Consumer Staples
- MOLN
- Exchange
- MED Nasdaq
- MOLN Nasdaq
- Market Cap
- MED 187.3M
- MOLN 195.4M
- IPO Year
- MED N/A
- MOLN 2021
- Fundamental
- Price
- MED $15.76
- MOLN $5.33
- Analyst Decision
- MED Hold
- MOLN
- Analyst Count
- MED 1
- MOLN 0
- Target Price
- MED $17.00
- MOLN N/A
- AVG Volume (30 Days)
- MED 223.4K
- MOLN 6.1K
- Earning Date
- MED 02-18-2025
- MOLN 03-13-2025
- Dividend Yield
- MED N/A
- MOLN N/A
- EPS Growth
- MED N/A
- MOLN N/A
- EPS
- MED 0.67
- MOLN N/A
- Revenue
- MED $674,475,000.00
- MOLN $7,105,397.00
- Revenue This Year
- MED N/A
- MOLN N/A
- Revenue Next Year
- MED N/A
- MOLN $29.41
- P/E Ratio
- MED $23.68
- MOLN N/A
- Revenue Growth
- MED N/A
- MOLN N/A
- 52 Week Low
- MED $14.94
- MOLN $3.32
- 52 Week High
- MED $57.41
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- MED 39.99
- MOLN 49.14
- Support Level
- MED $15.22
- MOLN $5.25
- Resistance Level
- MED $15.93
- MOLN $5.33
- Average True Range (ATR)
- MED 0.71
- MOLN 0.20
- MACD
- MED 0.03
- MOLN 0.02
- Stochastic Oscillator
- MED 28.47
- MOLN 44.23
About MED MEDIFAST INC
Medifast Inc is a United states based company that produces, distributes and sells products concerning weight loss, weight management, and healthy living. The company generates its revenue from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other consumable health and nutritional products.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.